+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07661966

Pilot Study of Bright Light Therapy Using an iPad Application for Patients Receiving First-Line Immune Checkpoint Blockade in Melanoma and Non-Small Cell Lung Cancer

Led by Weill Medical College of Cornell University · Updated on 2026-09-23

12

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether bright light therapy can help synchronize the natural sleep-wake cycles circadian rhythms of patients with melanoma or non-small cell lung cancer NSCLC receiving first-line immune checkpoint blockade ICB therapy. This pilot study focuses on testing the feasibility and safety of delivering bright light therapy through the Circadian OS iPad application before starting ICB treatment. The goal is to see if timing ICB therapy with synchronized circadian rhythms improves clinical outcomes, as disrupted rhythms may reduce immunotherapy response. Participants will receive 60 minutes of daily bright light therapy via the Circadian OS iPad app for at least seven days before beginning their planned ICB regimens, which may include anti-PD-1, anti-CTLA-4, or combinations with chemotherapy. This single-arm study monitors adherence to the therapy and its tolerability, aiming to entrain patients circadian rhythms to optimize immune function at the time of immunotherapy. During the study, researchers will track how many participants complete at least 70% of the bright light therapy sessions over a minimum of seven consecutive days before starting ICB treatment. They will also monitor adverse events related to the therapy up to the first ICB dose. Participants need reliable internet access to use the app, and the study duration before ICB initiation is expected to be about one to three weeks. The trial is sponsored by Weill Medical College of Cornell University and will run until December 2027.

CONDITIONS

Brief Title

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

Research Team

J

June Greenberg, BSN, RN, OCN, CCRP, CCRC

D

Daniella Topol, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here